Development of three tests for new strains of COVID-19 and avian influenza

Paris, France and Camberley, UK – 14 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) test for a new strain of COVID-19 and the development of two new RUO PCR tests for avian influenza following recent outbreaks

Visit Page

Développement de trois tests pour de nouvelles souches de la COVID-19 et de la grippe aviaire

Paris, France et Camberley, Royaume-Uni – 14 décembre 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste mondial du diagnostic clinique, annonce le lancement de son test de recherche (Research-Use-Only – RUO) d’amplification en chaîne par polymérase (PCR) pour une nouvelle souche de la COVID-19 et la mise au point de deux nouveaux tests PCR

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 2 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 1 December 2020 that, as at 30 November 2020 BlackRock Inc.’s holding in the Company on a voting and capital basis is 3.54% (2,500,373 shares). http://novacyt.com/wp-content/uploads/2020/12/Novacyt-BlackRock-holdings-02.12.2020.pdf

Visit Page